BUDAPEST, HUNGARY–(Marketwire – Oct 9, 2012) – ThalesNano is proud to announce that sales of its novel flow reactors reached 700 complete systems. The number of publications based on these flow reactors has also surpassed 150. First launched in 2005, ThalesNano offers a range of microscale flow based reactors used in chemistry research. The 700th unit, an H-Cube Pro, will be installed in Shanghai at a perfume and flavor manufacturer.
“We have always been focused on enabling chemists to achieve results with their chemistry that they cannot do with standard equipment,” said Richard Jones, CEO of ThalesNano Inc. “Whether it’s bringing back hazardous chemistry, such as hydrogenation, to the lab or enabling chemists to access a wider parameter space to synthesize novel molecules, ThalesNano has developed reactors to do this safer, faster, and simpler. On behalf of all employees at ThalesNano, let me express our gratitude to our customers who have contributed to our success and presence on 6 continents and in more than 30 countries.”
ThalesNano has recently launched the latest version of its best-selling R&D 100 award winner product, the H-Cube Pro. Several upcoming low cost reactor modules will expand the chemistry capabilities still further. Chemists can look forward to utilizing other gases such as carbon monoxide, oxygen, or Syngas on the same instrument they already use for their hydrogenations. The upcoming Phoenix Flow Reactor allows homogeneous reactions to be performed at higher than microwave temperatures and pressures. With the broadest range of flow reactors, ThalesNano is the “go to” company for flow chemistry.
ThalesNano is the world leader in bench-top flow chemistry reactors. The company has the widest portfolio of bench-top continuous process instruments for the pharmaceutical, biotech, fine chemical, petroleum/biofuel, and education markets. Its R&D 100 award winning H-Cube® and scale-up system H-Cube Mid™ are used in hundreds of laboratories globally and have become the new industry standard for hydrogenation. Within three years from the original introduction of its flagship H-Cube® product, 20 out of the top 20 pharmaceutical companies have introduced and adopted the technology.